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1. Introduction
ALL is a malignancy of lymphoid cells occurring at any age. Almost 5000 cases are diagnosed
annually in the USA. Cell-B subtypes account for 85–90% of cases in children and 75–80% of
cases in adults; T-lineage ALL accounts for a small proportion of cases. It has a bimodal
incidence occurring at 2–4 years of age followed by a gradual increase after the age of 50.
In  the  last  years  much  progress  has  been  made  in  understanding  the  biology  of  acute
lymphoblastic leukemia which is now recognized as an expanding group of heterogene‐
ous  entities.  Recognition  of  distinct  gene  expression  patterns  may  identify  patient  sub‐
group with unique response to therapy and prognosis.  Accurate definition of prognostic
subgroups based on cytogenetic molecular marker has allowed institution of risk orient‐
ed  therapies.  [2]  The  Philadelphia  (Ph1+)  chromosome was  first  described  in  1960  in  a
patient  with  chronic  myeloid  leukemia  (CML).  This  is  the  product  of  the  fusion  of
chromosomes 9 and 22, t (9;22), which results in a BCR-ABL hybrid gene. [2]
The incidence is approximately 20-30 % of adult patients with ALL who present the Philadel‐
phia (Ph) Chromosome. Whereas Ph+ ALL is rare in children, comprising less than 5% of acute
lymphoblastic leukemia, its incidence increases to approximately 40% in adults 40 years of
age, with a 10% increment for every further decade of life with no sex difference. The majority
of patients are diagnosed with de novo Ph+ ALL, although occasional cases of secondary Ph1+,
ALL have been reported following chemotherapy or radiation therapy. [3, 4]. There are no
known risk factors for Ph+ ALL. The associations with environmental socioeconomic infections
and genetic events are being studied extensively in ALL. Few causal links have been estab‐
lished and the etiology of ALL remains obscure in most cases. The strongest associations to
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date exist with genetic factors and the role of Epstein Barr virus (EBV) and human immuno‐
deficiency virus (HIV) in patients with mature B cell ALL [2].
2. Diagnosis
The characteristic findings of Ph1+ ALL is a reciprocal translocation t(9,22) (q34q11) that fuses
the BCR gene from chromosome 22 to the ABL gene from chromosome 9. By standard
cytogenetic analysis this becomes apparent as a shortened chromosome 22 referred to as the
Philadelphia chromosome, which can also be visualized by fluorescent in situ hybridization
(FISH) analysis. At the molecular level, the bcr/abl fusion transcript can be detected by RT-
PCR. The location of the breakpoint within the BCR gene results in either the p190 BCR/ABL protein
observed in Ph+ ALL (66.3% of the cases) or the p210 BCR/ABL protein common to patients with
Ph+ CML which is present in ALL Ph+ (31,2%) The remaining cases are associated either with
both transcript type or with atypical transcripts. [4]
Other additional chromosome aberrations were present in up to 79% of the cases in a large
study  of  209  patients  (Moorman et  al).  Yanada  et  al.  study  involving  77  Ph+  ALL pa‐
tients, additional aberrations with a frequency of greater than 10% included a second Ph
chromosome (+der(22)  t  (9,22))  abnormalities  involving the short  arm of  chromosome 9,
monosomy 7, and trisomy 8. The presence of additional aberrations was associated with
significantly shorter relapse free survival (RFS) and higher relapse rate. This was particular‐
ly pronounced for the +der (22)t(9,22) and abnormalities involving the short arm chromo‐
some 9.  In  reference  to  this,  standard  karyotyping  is  mandatory  to  establish  the  initial
diagnosis while FISH analysis may be used as a confirmatory technique. The major role of
PCR  analysis  at  diagnosis  is  determination  of  the  type  of  fusion  transcript,  which  be‐
comes relevant during follow up studies of MDR. Using only PCR to establish the diagnosis
is  not  acceptable,  even  more  so  as  occasional  patients  harbor  an  aberrant  fusion  tran‐
script that is not detected by standard primer combination [5,6.]
The white blood cell count is variable at diagnosis, hyperleukocytosis and/or splenomegaly
may be present. Ph+ ALL is a B-precursor ALL which typically expresses the CD19 and CD10
antigens, and the CD34 antigen is expressed in 89% of cases. The most frequent immunologic
subtypes are common ALL (78.2%) and pre-B ALL (19.9%), whereas only 1.9% of patients
display the pro – B immunophenotype. Except for few case reports, the chromosome is not
found in T linage ALL. Myeloid markers are frequently expressed, most notably the CD13
antigen (20%) and CD33 antigen (15%). CNS leukemia is infrequent (5%) at initial presentation,
but there is an increased risk of developing meningeal leukemia during the course of treatment
when compared with other B linage ALL. [7]
The main differential diagnosis at the begime,of the disease is chronic myelogenous leukemia
(CML) lymphoblastic blast crisis (LBC). In the absence of a history of CML, myeloid hyper‐
plasia, bone marrow basophilia, eosinophilia or excessive splenomegaly are suggestive of LBC-
CML. While identification of the e1a2 fusion product (p190 BCR-ABL) essentially rules out CML,
the major BCR fusion transcript (p210 BCR-ABL) is found in both Ph+ ALL and LBC-CML. This
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distinction is usually of no clinical significance. However, as newly diagnosed LBC-CML
without a prior history of CML is generally treated in the same way as Ph+ ALL. [8]
3. Treatment of Ph 1+ ALL: The result with Imatinib and chemotherapy
Chemotherapy alone for adult with ALL Ph1+ is poor, with less than 10% probability. Long
term survival. The development of tirosi kinase inhibitor, imatinib and its use with chemo‐
theray for the induction obtained complete remission in ranged from 60-70%, moderately
lower than 70-90 % achieved in Ph1+ negative ALL. The median CR duration was considerably
inferior, however ranging from 9-16 month in patients treated only with chemotherapy with
almost no long term survivor. Because of the poor outcome with chemotherapy, the allogeneic
stem cell transplantation (SCT) is considered to be the treatment of choice in adult Ph+ ALL. [9]
Imatinib Mesylate (STI571 GlivecR) (IM) was the first Tirosin Kinase inhibitor for CML
treatment and now is the gold standard for the treatment of de novo CML in chronic phase.
The BCR/ABL fusion gene encodes the chimeric BCR/ABL oncoprotein which has constitu‐
tively active tyrosine kinase activity. This results in dysregulated activity of additional signal
transduction pathways located downstream of BCR/ABL. The strong pathophysiological
similarity between Ph+ ALL and CML provided the rationale for exploring the clinical efficacy
of IM. [10].
Druker et al. in one of the first evidence of clinical activity from a phase I study in 2001, in
relapsed or refractory patients with Ph+ ALL which showed a significant number of hemato‐
logical responses (70%) although only 20 % of the patients achieved a complete remission (CR).
Later in 2002 these results were confirmed in phase II studies in which imatinib at daily doses
of 400 mg to 600 mg induced a CR in 19% of the patients. These responses were not sustained
however, and the estimated median survival in these studies was only 4.9 months. As a
consequence, subsequent studies focused on the use of imatinib during front line therapy of
Ph+ ALL, both as a single agent therapy and in combination with various chemotherapy
regimens. A major goal of studies performed in younger patients was to increase the CR rate
and improve the quality of response prior to hematopoietic stem cell transplantation (HSTC)
in patients with a suitable donor. [12,13]. Several strategies have been evaluated to optimize
the combination of imatinib and chemotherapy. Initial studies were based on schedules
alternating imatinib and chemotherapy cycles followed by clinical trials that investigated
schedules in which imatinib and chemotherapy were given concomitantly. The question of
whether minimization of chemotherapy related toxicity by combining imatinib with less
intensive chemotherapy or administering it alone yielded equivalent or superior results was
also addressed. [11]
The current standard approach for patients in the combination of a chemotherapy protocol
employing four to five cytotoxic agents typically used for ALL with imatinib at a daily dose
of 400 mg to 800 mg (Table 1). Complete remission rates in these studies consistently exceeded
90%, the profile and incidence of severe toxicity were not different from those associated with
the historic chemotherapy alone regimens. The overall survival (OS) in the different studies
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ranged from 36 to 76 %, although follow up is short (1-3 years) while the superiority of adding
imatinib to conventional chemotherapy was strongly suggested by historical comparisons
between the outcome of the patients using similar chemotherapeutic schedules with or without
imatinib the impact of imatinib based regimen on long-term outcome is difficult to assess due
to the higher rate of patients undergoing SCT in CR1, which became possible due to a lower
incidence of early relapses. [10]
        Imatinib dosing       Results (%)
Subtype
Chemotherapy 
regimen
Induction 
(mg/d)
Consolidation   
(mg/d)
Mantenance 
(mg/d) No CR Relapse
DFS       
(at y)
Survival    
(at y)
Adults
Thomas el al Hyper-CVAD C (400) C (400) C (400) 39 92 14 83(3) 55 (3)
Yanada el al JALSG ALL202 C (600) A (600) C (600) 80 96 26
60 (1)     
51 (2)
76 (1)       
58 (2)
Lee et al
Modi fied from 
Linker C (600) C (400) C (400) 20 95 32 62 (2)        59 (2)
Wassmann et al
GMALL                           
Al ternating 
Concurrent 
None          
None
A (400/ 600)       
C (600)
NR              
NR
47          
45
NA        
NA
NR        
NR
52 (2)      
61 (2)
36 (2)       
43 (2)
de Labarthe el al GRAAPH-2003 None          C (600) NR                      45 96 19 51 (1.5) 65 (1.5)
Ottmann et el al
GMALL                           
Chemotherapy 
Imatinib
None        
Only (600)
C (600)           
C (600)
C (600)          
C (600)
28          
27
96        
50
41         
54
29 (1.5)    
57 (1.5)
35 (1.5)     
41 (1.5)
C= concurrent; A= alternating; NR= not reported; NA= not applicable; JALSG = Japan Adult Leukemia Study Group; GMALL= German Multi-Centre Acute
Lymphoblastic Leukemia; hyper-CVAD= fractionated cyclophosphamide, vincristine, doxorubicine, dexamethasone; GRAAPH= Group for Research on 
Adult Acute Lymphoblastic Leukemia; GIMEMA= Gruppo Italiano Malattie Ematologiche dell´Adulto; GRAALL=Group for Research in Adult Acute 
Lymphoblastic Leukemia; Pred= prednisone 
C= concurrent; A= alternating; NR= not reported; NA= not applicable; JALSG = Japan Adult Leukemia Study Group;
GMALL= German Multi‐Centre Acute; Lymphoblastic Leukemia; hyper‐CVAD= fractionated cyclophosphamide,
vincristine, doxorubicine, dexamethasone; GRAAPH= Group for Research on Adult Acute Lymphoblastic Leukemia;
GIMEMA= Gruppo Italiano Malattie Ematologiche dell´Adulto; GRAALL=Group for Research in Adult Acute Lympho‐
blastic Leukemia; Pred= prednisone
Table 1. Studies combining imatinib with chemotherapy for de novo Philadelphia chromosome positive (Ph+) ALL [10]
4. Approach in young patients
4.1. Imatinib in combination with chemotherapy in younger patients
The current standard approach for young patients is the combination of chemotherapy
protocol employing four to five cytotoxic agent typically used for ALL with imatinib at a daily
dose of 400 to 600 mg. Such an approach was pioneered by the MD Anderson Group. They
combined sequential imatinib at 400 mg with 8 alternate hyper-CVAD and HD-MTX/AraC
cycles (fractionated Cyclophosphamide, Vincristine, Doxorubicin and Dexamethasone
alternating with cycles of high dose Methotrexate and Cytarabine) followed by imatinib
maintenance at 600 mg/d. In this trial the CR rate was 93% with about 2 years of DFS rate of
75%. The molecular remission rate or negativity for bcr/abl transcript by RT-PCR and nested
PCR approach 60%. [14]
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Yanada et al. have likewise reported results in complete remission (CR) in 77 patient (96.2%),
as well as polymerase chain reaction negativity of bone marrow in 71,3 % with the use a
multidrug protocol plus imatinib. The authors described that the profile and incidence of
severe toxicity were not different from those associated with our historic chemotherapy-alone
regimen. Relapse occurred in 20 patient after median CR duration of 5,2 months. 49 patients
underwent the allogeneic hematopoietic stem cell transplantation (HSCT), 39 of whom
underwent transplantation during their first CR. The 1 year-event-free and overall survival
(OS) rates were estimated to be 60.0% and 76.1%, respectively, which were significantly better
than ourfortheir historic controls treated with chemotherapy alone. The probability of OS for
this group of patients described by the author at 1 year was 73.3 % for those who underwent
allogeneic HSCT and 84.8% for those who did not. [15]
Lee K-H et al. evaluated 20 patients with Ph+ ALL who were administered with induction
chemotherapy daunorrubicin, vincristine prednisolone and L asparaginase along with
imatinib 600 mg /day during remission induction and 400 mg /day during consolidation
courses. 19 patients achieved complete remission (CR). In this trials, 15 underwent allogeneic
hematopoietic cell transplantation (HCT) during first CR. After median follow up period of
799 days, 6 patients experienced recurrence. Eight died. Median CR duration was 821 days
and median patient survival was 894 days. In the study the results were significantly longer
by 2.9 and 2.3 fold respectively when compared to those of 18 historical patient treatments
with same regimen of combination chemotherapy without imatinib. [16]
Wassmann et al. enrolled 92 patients with newly diagnosed Ph+ ALL in a prospective multi‐
center study to investigate sequentially 2 treatment schedules with imatinib administrated
concurrent to or alternating with a uniform induction and consolidation regimen. Coadmi‐
nistration of imatinib and induction cycle2 (INDII) resulted in a CR rate of 95 % and polymerase
chain reaction (PCR) negativity for BCR/ABL in 52 % of the patients compared with 19% in
patients in the alternating treatment cohort. Remarkably, patients with and without a CR after
induction cycle 1 (INDI) had similar hematologic and molecular responses after concurrent
imatinib and INDII. 7 % of the patients underwent allogeneic stem cell transplantation (SCT),
in first CR (CR1) both schedules of imatinib had acceptable toxicity and facilitated SCT in CR1
in the majority of patients but concurrent administration of imatinib and chemotherapy had
greater antileukemic efficacy for this group. [17]
Labarthe et  al.  in 2007 published the results  of  45 patients  with Ph+  ALL treated in the
Group  for  Research  on  Adult  Acute  Lymphoblastic  Leukemia  (GRAAPH)  2003  study,
where imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine)
as  consolidation  therapy  in  good  early  responders  (corticosensitive  and  chemosensitive
ALL)  or  earlier  during  the  induction  course  in  combination  with  dexamethasone  and
vincristine  in  poor  early  responders  (corticoresistant  and/or  chemoresistant  ALL).  Imati‐
nib  was  then  continuously  administered  until  stem  cell  transplantation  (SCT).  Overall,
complete  remission (CR)  and BCR-ABL  real-time quantitative  polymerase  chain  reaction
(RQ-PCR) negativity rates were 96% and 29%, respectively. All of the 22 CR patients (100%)
with a donor received allogeneic SCT in first CR. At 18 months, the estimated cumulative
incidence of relapse, disease-free survival, and overall survival were 30%, 51%, and 65%,
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respectively.  The  authors  described  these  3  end  points  were  favorable  compared  with
results obtained in the pre-imatinib LALA-94 trial. [18]
Ottmann et al. recognized the potential benefit of administering imatinib simultaneously with
chemotherapy rather than in an alternating manner which was investigated in two successive
cohort of patients who were treated according to GMALL protocol and received imatinib either
alternating with chemotherapy (first cohort) or simultaneously with induction and consoli‐
dation cycles (second cohort). The reported rate of complete molecular remission (CMR) was
19% and 52 % respectively, but this greater antileukemia efficacy did not translate into
significant improvements in DFS or overall survival. [19] So far, the analyzed data showed the
superiority of adding Imatinib to conventional chemotherapy and it was strongly suggested
by historical comparison between the outcome of the patients using similar chemotherapeutic
with or without imatinib. The magnitude of improvement was as high as 30% in the studies
from MD Anderson and the GRAALL. These results were also confirmed by a pediatric study
of Schultz et al. in which imatinib was given at 340 mg/m2 for an increasing number of days
in combination with intensive chemotherapy. Early (1 year) EFS improved with increasing
imatinib exposure from 70% to 95%. [20]
5. Imatinib-based therapy in elderly patients
5.1. Approach in older patients
While the strategy of combining imatinib with standard intensive chemotherapy protocol was
explored primarily in younger patients, therapeutic approaches in elderly patients were
focused more on reducing the intensity of chemotherapy. Vignetti et al. by GIMEMA
(LAL0201) initiated a study with 30 patients who received a prephase with prednisone at
increasing doses from 10 to 40 mg/m2/day followed by 45 day induction treatment with
imatinib at the fixed dose of 800mg /day in combination with oral prednisone (40mg/m2/day)
followed by maintenance with imatinib in all responding patients until occurrence of disease
relapse or excessive toxicity. Complete remission was achieved in all patients (n=29). median
survival from diagnosis was 20 month. In this study, the authors showed that elderly Ph(+)
patients with ALL, often considered eligible only for palliative treatment strategies,may benefit
from an imatinib-steroids protocol, which does not require chemotherapy or a long hospital‐
ization; it is feasible, highly active, and associated with a good quality of life. [21]
Dalannoy et al., in another study from the GRALL (AFRO9 study), are currently testing a low
intensity schedule (vincristine and dexamethasone), in combination with high dose imatinib
(800mg/d) in elderly patients above 55 years (DIV regimen). Thirty patients were included in
this study and were compared with 21 historical controls. Out of 29 assessable patients, 21
(72%9) were in CR after induction chemotherapy vs 6/21 (29%) in control. Five additional CRs
were obtained after salvage with imatinib and four after salvage with additional chemotherapy
in the control group. Overall survival (OS) was 66% at 1 year vs 43% in the control group. The
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1 year- relapse-free survival is 58 vs 11%. The author showed that the use of imatinib in elderly
patients with Ph+ ALL is very likely to improve outcome, including OS. [22]
A pilot study of these combinations had shown promising results in relapsing and refractory
Ph+ ALL with a CR rate of 90% in patients older than 55 years. This group, considers the
hypothesis that Imatinib, combined with high-dose chemotherapy, is now becoming the gold
standard for treatment of Philadelphia chromosome-positive acute leukemias. However, in all
studies, imatinib dosage was tapered to 400–600 mg per day.) The group decided to initiate a
clinical trial to evaluate an opposite strategy based on high-dose imatinib (800 mg per day)
combined with a less intensive chemotherapeutic regimen (vincristine and dexamethasone),
which we called the DIV induction regimen. Thirty-one patients (18 relapsing or refractory Ph
+ acute lymphoblastic leukemias and 13 lymphoid blast crisis chronic myelogenous leukemias)
were enrolled. Complete remission (CR) was obtained in 28 out of 30 assessable patients. The
median bcr-abl/abl ratio after the induction course was 0.1%. Median time to neutrophil
recovery was 21 days. Nine out of 19 patients under 55 years old received allogenic stem cell
transplantation after a median time of 78 days post-CR. Patients older than 55 experienced a
90% CR rate without additional toxicities, suggesting the DIV regimen may also be proposed
as a front line therapy in older patients.[23]
6. Dasatinib in combination with chemotherapy
The combination of dasatinib with a variety of cytotoxic chemotherapy regimen both in
younger and elderly patients with de novo or minimally pretreatment Ph+ ALL was explored
in different groups of treatment. Ravandi et al. in one study phase II trial, showed patients
with newly diagnosed Ph+ ALL who received dasatinib 50 mg PO BID (or 100 mg daily) for
the first 14 days of each of 8 cycles of alternating hyperCVAD and high dose cytarabine plus
methotrexate. Patients in CR continue to receive maintenance dasatinib 50 mg po BID (or 100
mg daily) and vincristine and prednisone monthly for 2 years followed by dasatinib indefi‐
nitely. With a median follow up of 10 months, 21 pts were alive and 18 were in CR; 2 died at
induction, 3 pts died in CR; 1 from an unrelated cardiac event and 2 from infections. 5 pts
relapsed (response durations were 54, 48, 47, 32, and 22 weeks) and 2 of them died. In 2 pts
morphological relapse was preceded by flow and molecular relapse. Four relapsed pts
        Imatinib dosing       Results (%)
Subtype
Chemotherapy 
regimen
Induction 
(mg/d)
Consolidation   
(mg/d)
Mantenance 
(mg/d) No CR Relapse
DFS       
(at y)
Survival    
(at y)
Adults
Vinetti  el  al GIMEMA +Pred (800) Only (800) Only (800) 30 100 48 48 (1) 74 (1)
Delannoy
GRAALL                    
AFR09
None C (600) A (600) 30 72 60 58 (1) 66 (1)
Réa el  al
GRAALL                    
AFR07 pi lot C (800) C (600) C (600) 31 90 NR 48 (1) 60 (1)
Table 2. Studies combining imatinib with chemotherapy for de novo Philadelphia chromosome positive (Ph+) ALL in
Elderly Patients [10]
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developed new ABL mutations (3 T315I and 1 F359V). One patient underwent an allogeneic
stem cell transplant. The author concluded that Dasatinib with HyperCVAD is effective in
achieved molecular remission in patients with Ph+ ALL. They also found high incidence of T
315I ABL mutation among the relapsed patients. [24]
Reference N (evaluated)
Age   
(range)
Dasatinib    
mg/d
ChThx            
regimen
Schedule of TKI 
and ChThx CR %
PCR 
negative     
%
Induction 
death,  
n(&)
Relapse   
% Outcome
Ravandi F          
2008
28* 52(21-79) 100 QD HyperCVAD D1-14 of e/cycle 93 50 2(7) 5(18) CR (10m):18 (64%)     OS (10): 21 (75%
Rousselot P   
2008 22 71 (61-83)
140 QD        
100 QD EWALL elderly
IND: parallel, 
then 95 28 1 (4.5) 1 (4.5) na
Foa R                
2008 48 (34) 54 (24-76) 70 BID 
Steroid prephase 
then 12 w 
Post-Induction 
therapy not 100 na 0 9 (27) OS (10): 81%
*22 patients with de novo Ph+All, 6pts, with one prior treatment cycle
OS indicates overall survival; CR, complete remission; ChThx, chemotherapy; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; IND, induction;
na, not applicable; EWALL; European Working Group for Adult of the Europena LeukemiaNet
*22 patients with de novo Ph+All, 6pts, with one prior treatment cycle, OS indicates overall survival; CR, complete
remission; ChThx, chemotherapy; hyper‐CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexametha‐
sone; IND, induction; na, not applicable; EWALL; European Working Group for Adult of the Europena LeukemiaNet
Table 3. Studies with dasatinib for de novo Philadelphia chromosome + (Ph+) ALL.
In another study, Rousselot et al. evaluated that after a pre-phase with dexamethasone 10 mg/
m2 d-7 to d-3, dasatinib was administered at 140 mg QD (100 mg in patients over 70y) during
the induction period in combination with IV injections of vincristine 1 mg and dexamethasone
40 mg 2 days (20 mg over 70y) repeated weekly for 4 weeks. Consolidation cycles consisted of
dasatinib 100 mg/d administered sequentially with methotrexate 1000 mg/m2 IV d1 (500
mg/m2 over 70y) and L-asparaginase 10,000 UI/m2 IM d2 (5,000 UI/m2 over 70y) for cycles 1, 3
and 5 and cytarabine 1,000 mg/m2/12h IV d1, d3, d5 (500 mg/m2 over 70y) for cycles 2, 4 and
6. Maintenance phase consisted of dasatinib alternating with 6-MP and methotrexate orally
every other month and dexamethasone/vincristine once every 2 months for up to 24 months.
Median RFS and OS were 22.1 and 27.1 months, respectively. The group also showed dasatinib
with low-intensity chemotherapy was highly effective in elderly patients with Ph+ ALL with
a 90% CR and 22.1 months RFS. In concordance with Ravandi et al. the mutation T315I was
associated with relapses. [25]
In these studies the CR rates were from 93 % until 100% independent of the regimen used, with
molecular remission rates from 28% to 72%.
7. Dasatinib monotherapy
Dasatinib was used without chemotherapy. In this modality Foa el al by GIMEMA LAL1205
protocol, the patients with newly diagnosed Ph+ ALL older than 18 (with no upper age limit)
received dasatinib 70 mg BID IN induction therapy for 84 days combined with steroids for the
first 32 days and intrathecal chemotherapy. Post-remission therapy was free. Fifty-three
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patients were evaluable. All patients achieved a complete hematologic remission (CHR), 49
(92.5%) at day 22. At this time point, 10 patients achieved a BCR-ABL reduction to < 10−3. At
20 months, the overall survival was 69.2% and disease-free survival was 51.1%. A significant
difference in DFS was observed between patients who showed a decrease in BCR-ABL levels
to < 10−3 at day 22 compared with patients who never reached these levels during induction.
No deaths or relapses occurred during induction. Twenty-three patients relapsed after
completing induction. A T315I mutation was detected in 12 of 17 relapsed cases. Treatment
was well tolerated; only 4 patients discontinued therapy during the last phase of the induction
when already in CHR. In adult Ph+ ALL, induction treatment with dasatinib plus steroids is
associated with a CHR in virtually all patients, irrespective of age, good compliance, no deaths,
and a very rapid de bulking of the neoplastic clone.[26]
8. Maintenance therapy
To date there is no consensus as to what constitutes the most effective maintenance therapy in
patients in whom allogeneic SCT is not possible. The recommendations of the European
Working Group for Adult ALL provide no recommendations for maintenance therapy in
patients not eligible for allogenic stem cell transplantation. Usually Imatinib is given either
alone or in combination with classical ALL maintenance such as low dose methotrexate and
6-mercatopurine. However, data on the efficacy of these strategies is scarce. [22]
Potenza et al. in a study, with seven patients with Ph+ ALL who were in first complete
remission and received maintenance therapy with imatinib alone, at 2 year progression free
survival was 75%. The qPCR monitoring of BCR/ABL, persisting molecular complete response
was associated with long lasting CR. The molecular relapse did not invariably mean hemato‐
logical relapse and only the wide and rapid increment of BCR/ABL values was predictive of
leukemia relapse. [27]
However, larger studies show less favorable results with Imatinib based maintenance.
M D Anderson employed more intensive maintenance therapy. They used imatinib 800 mg
for 24 months with monthly vincristine and prednisone interrupted by 2 intensifications with
Hyper-CVAD and imatinib, then imatinib indefinitely. [10]
The GMALL A and GRAAL presented an interesting approach in which imatinib is given
concurrently with standard dose of Interferon or peg –Interferon. Wassmann et al. had a
hypothesis that the experimental data suggested that interferon-α (IFN-α) enhances the
antileukemic activity of imatinib. Therefore, the group combined imatinib and low-dose IFN-
α in six patients with Ph+ ALL who were ineligible for stem cell transplantation. All patients
had received imatinib for 0.5–4.8 months prior to IFN-α, for relapse or refractory Ph+ ALL or
as an alternative to chemotherapy following severe treatment related toxicity. The results were
encouraging, but longer follow up is needed to determine whether this strategy will translate
into better relapse free survival. [28-29]
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Longer follow up is needed to determine if this strategy will translate into better relapse-free
survival. The European recommendation concluded that the standard approach to de novo Ph
+ ALL is the combination of intensive chemotherapy with imatinib (400 mg/d to 800/d) in
young patients and reduced dose of chemotherapy with high dose imatinib (600 mg/d to 800
mg/d) for elderly patients. Allogeneic SCT is recommended to all eligible patients with a
suitable donor and to continue imatinib with or without additional therapy in patients not
undergoing SCT.[30]
9. Central nervous system (CNS) prophylaxis
Central nervous system leukemia is infrequent (5%) at initial presentation, but there is
significant risk of developing meningeal leukemia during the course of treatment and the CNS
directed prophylactic therapy should be considered mandatory in this patients.
Imatinib does not cross the blood brain barrier to an appreciable extent, levels in the cerebro‐
spinal fluid have shown to reach approximately 1 - 2 % of serum level. This low degree of
penetration into the CNS is most likely due to p-glycoprotein export pumps, and it is not
increased in the setting of active meningeal leukemia. Therefore, active CNS directed prophy‐
lactic therapy is mandatory in all patients with Ph+ ALL. Both repeat intrathecal injection of
chemotherapy e.g. methotrexate, alone or in combination with cytarabine and corticosteroid,
and prophylactic cranial irradiation have been used successfully. There is currently no
conclusive data whether for how long and at what interval intratecal chemotherapy should be
continued in patients with sustained hematological even molecular remission and whether it
may be prudent to administer some form of CNS prophylactic after SCT.[31,32]
Dasatinib showed in the clinical trials CA180006 better penetration of the CSF and achieved
clinically active concentrations in small series of patients in whom stabilization and regression
of CNS disease were achieved. The doses of Dasatinib 140 mg once a day or 70 mg twice a day.
It remains to be determined whether the current approach to CNS directed prophylaxis can
be modified in the context of dasatinib based treatment.[33]
10. Mechanism of resistance to therapy and progression
The mechanism of resistance to therapy is related to acquired genetic abnormalities in Ph+
ALL blast cells, which provide insights into pathogenesis and strongly influence prognosis.
Cytogenetic abnormalities in addition to the Ph+ chromosome are present in approximately
one third of cases of adult leukemia. Other Overexpression of bcr/abl fusion gene e.g. due to
double Ph+ chromosome, activates a number of downstream signaling pathways involving
the Ras/Raf/mitogen activated protein kinase and JAK-STAT (Janus Kinase signal transducer
and transcription activator of transcription) development of growth factor independent
malignant clones contributes to progression of the disease. [34]
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11. Relapse associated with a BCR-ABL kinase domain point mutation
The  development  of  clinical  resistance  to  imatinib  has  now  surfaced  in  several  sites.
Acquisitions of point mutations in the ABL tyrosine kinase domain (KD) that interfere with
the binding of imatinib appear to be the most influential. ABL KD mutations generally are
comprised  of  two  categories.  The  first  includes  mutations  that  directly  impede  contact
between imatinib and Bcr-Abl, such as the gatekeeper mutations T3151 or F317L. [35] The
second involves  mutations  that  alter  the  spatial  conformation of  the  Bcr-Abl  protein  by
affecting one of the two flexible loops: (1) the P-loop containing the ATP binding pocket,
or (2) the activating loop. [36.37.38] To date, more than 50 ABL KD mutations have been
identified. Although the prognostic significance of many of these remains unclear, the T315I
mutation  has  been  associated  with  a  particularly  adverse  outcome  since  it  disrupts  a
hydrogen bond critical  for binding the TKI to the ATP- binding site.  It  has been identi‐
fied in up to 20% of patients with imatinib-resistant Ph+ ALL, and also confers resistance
to the second-generation TKIs nilotinib and dasatinib.[39]
In the GMALL study for elderly patients with Ph+ ALL, the incidence of ABL mutations by
direct cDNA sequencing at the time of disease recurrence was 84%. In patients with ABL KD
mutations, P-loop mutations predominated at a frequency of 57%, followed by the T315I
mutation at 19%. The mutated clone comprised more than 50% of the ABL clones in all patients.
[20] Pfeifer et al. also demonstrated that these ABL KD mutations were present in nearly 40%
of the patients with de novo imatinib-naïve Ph+ ALL, with a distribution of P-loop mutations
in 80% and the T315I mutation in 17%. However, the mutated ABL clone always comprised
less than 2% of the sample, in contrast to the predominance of the mutated clone when
associated with disease recurrence. These low-level ABL KD mutations in imatinib-naïve
samples required more sensitive methods for detection (e.g., high-performance liquid chro‐
matography). The presence of ABL KD mutations prior to imatinib did not correlate with
known prognostic factors. There was no difference in the probability of achieving CR or
molecular response based on the presence or absence of ABL KD mutations prior to imatinib
therapy. No difference in remission duration was observed other than for those with the T315I
mutation, which adversely affected outcome. In nearly all patients with an ABL KD mutation
identified pretreatment, the same mutation was noted at the time of disease recurrence.
Approximately 67% of the patients without an ABL KD mutation detected prior to imatinib
had developed one at the time of disease recurrence. The discovery of novel acquired ABL KD
mutations had also been reported in Ph+ ALL after sequential therapy with imatinib followed
by the second-generation TKI dasatinib.[39]
Soverini et al. reported the development of the T315A and F317I (as opposed to the T315I or
F317L) mutations that have inherent resistance to dasatinib. These ABL KD mutations could
be suppressed by either imatinib or nilotinib given the lower IC50 with these compounds,
although retreatment with imatinib after a prior failure would likely be ineffective due to the
potential role of other coexisting mechanisms of resistance. Resistance screening with nilotinib,
the other second-generation TKI, yielded only a limited spectrum of point mutations.[40] This
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suggests a lower rate of ABL KD mutations after Nilotinib therapy; however, additional
analyses of ongoing clinical trials are needed to support this contention. [41]
Other mechanisms of resistance to imatinib and other TKIs include increased drug efflux,
amplification of the BCR-ABL gene, and signaling independence of BCR-ABL after secondary
transforming events (e.g., Src kinase pathway). Theoretically, dose escalation of imatinib or
the use of more potent ABL inhibitors could circumvent the first two events, whereas use of
novel Src inhibitors or multitargeted inhibitors would be required to restore sensitivity in the
latter case [42]
12. Clinical implications of MRD
High levels of bcr-abl transcripts at different treatment stages indicate poor responsiveness to
chemotherapy and to TKI, and intuitively could be considered a risk factor for disease
recurrence. However, published data is not consistent. MRD levels determined at different
time points prior to alloSCT were found to have prognostic relevance, with an early reduction
in BCR-ABL transcript levels of at least 3 log appearing as the most powerful predictor of lower
relapse rate and better DFS. The authors demonstrated the positive impact of imatinib on the
outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-
positive acute lymphoblastic leukemia (Ph-positive ALL)and analyzed for risk factors that
affect transplantation outcome, and they focused particularly on the prognostic relevance of
minimal residual disease levels at each treatment stage. Prospective assessment of the extent
of minimal residual disease reduction after the first 4-week imatinib therapy may allow the
authors to identify subgroups of Ph-positive ALL transplants at high risk of relapse. [45]
Stratification based upon MRD levels was also the principal prognostic parameter in two
studies, Dombret H. et al. with 154 patients, and Pane F et al with 45 Ph+ ALL patients,
respectively. [43,44,45,46]
In contrast, prospective MRD monitoring in 100 adult patients with Ph+ ALL treated with
uniform imatinib- combined chemotherapy failed to establish an association between PCR
negativity at the end of induction therapy and either relapse rate or relapse-free survival,
although an increase in bcr-abl transcripts during hematologic CR was predictive of relapse
in non-transplanted patients. [47]
Despite these discrepancies, these studies demonstrate that prospective monitoring of MRD
has the potential to identify patients at risk of relapse, although the implication of different
transcript levels and increments require validation within each therapeutic context or clinical
study. These issues highlight the need for standardization and harmonization of methodolo‐
gies used for bcr-abl quantification in Ph+ ALL. To achieve this aim at an international level,
regular quality control rounds are jointly conducted by the European Working Group for
Adult ALL (EWALL) of the European LeukemiaNet and the European Study Group for MRD
Analysis in Acute Lymphoblastic Leukemia.
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13. Treatment to relapse
Point mutations are the major mechanism of resistance to Imatinib therapy in Ph+ leukemia;
different drugs active on mutant BCR/ABL or on its signal transduction pathway have been
developed and tested at clinical level. Several second-generation ABL TKIs possess significant
activity against imatinib-resistant BCR/ABL mutants, although their specificities vary.[48]
Dasatinib has been tested most extensively in Ph+ ALL and has been approved as second-line
treatment of bcr-abl–positive leukemias in first time. Dasatinib (formerly BMS-354825) is a
multitarget kinase inhibitor of Bcr-Abl, SRC family kinases, ephrin receptor kinases, PDGFR
and KIT, among others. In a phase II study, dasatinib induces rapid hematologic and cytoge‐
netic responses in adult patients with Ph+ ALL with resistance or intolerance to imatinib.[49]
Non-hematological side effects include diarrhea, nausea, headache, peripheral edema and
pleural effusion. However, remission duration and PFS were short, due to resistance that was
often associated with appearance of the T315I mutation. To enhance efficacy, dasatinib was
combined with the hyperCVAD chemotherapy regimen in a phase II study with 14 patients,
3 of whom had CNS involvement. [50]
All patients responded; 71% achieved a CR, 64% achieved a major molecular response. With
a median follow-up of 6 months, 7 patients remained in CR/CRp. Although toxicity was
significant, with several episodes of gastrointestinal and subdural hemorrhage and pleural
effusions, these preliminary results suggested that combination therapy should be preferred
over single-agent therapy; alloSCT should be the goal if at all possible. To achieve a CR,
mutation analysis should precede salvage therapy, and experimental treatment should be
considered if the T315I mutation is detected, as this mutation confers resistance to all second
generation ABL TKI. [50]
Small-molecule inhibitors developed to target Aurora kinases (AK), a family of serine-
threonine kinases involved in the control of chromosome assembly and segregation during
mitosis, have been found to possess activity against the T315I mutation. Several of these novel
AK inhibitors have recently entered preclinical or clinical testing.. [51.52]
Another novel chemical class of compounds that bind to different structural pockets used by
ABL kinase to switch between the inactive and active conformations, have recently been
developed using structure-based drug design. Compounds have emerged that potently inhibit
purified ABL in both the unphosphorylated and phosphorylated states via a non-ATP-
competitive mechanism and impair proliferation and induce apoptosis of cells expressing a
wide variety of BCR-ABL TKI-resistant mutants, including the T315I mutant, many P-loop
mutants, and the dasatinib- resistant mutant F317L. [53]
14. New kinase inhibitors
Ongoing and future clinical trials will establish whether front-line therapy with second-
generation ABL kinase inhibitors, ie, dasatinib, nilotinib, bosutinib and Inno-406, are superior
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to imatinib. Results may differ depending on their use as single-agents or as components for
combination therapy. SCT-independent immunotherapeutic approaches are also evolving.
Bispecific T cell–engager (BiTE) antibodies that transiently engage cytotoxic T cells for lysis of
selected target cells are among the most interesting agents for immunotherapy of Ph+ ALL.
The bispecific antibody construct called blinatumomab links T cells with CD19-expressing
target cells, resulting in a non-restricted cytotoxic T-cell response and T-cell activation. A phase
II dose-escalating study investigating the efficacy and safety of blinatumomab in ALL patients
who are in complete hematological remission but remain MRD-positive is ongoing. Prelimi‐
nary results indicate that treatment with blinatumomab is well tolerated and able to convert
MRD- positive ALL into an MRD negative status. [54]
As a conclusion, our armamentarium of drugs that hold promise as active agents for treating
Ph+ ALL is expanding substantially. Studies will need to focus on drug combinations, with
specific attention to sequence and dosing of these agents. In designing trials, treatment
algorithms should increasingly be based on molecular markers of disease and utilize quanti‐
tative assessment of MRD, and highly sensitive detection of mutations.[55]
15. Conclusion
The  tyrosine  kinase  inhibitor  (TKI)  imatinib  has  become  an  integral  part  of  front-line
therapy for Ph+ ALL, with remission rates exceeding 90% irrespective of whether imati‐
nib  is  given  alone  or  combined  with  chemotherapy.  Treatment  outcome with  imatinib-
based regimens has improved compared with historic controls, but most patients who do
not undergo allogeneic  stem cell  transplantation (SCT) (see the next  chapter)  eventually
relapse. Acquired resistance on TKI treatment is associated with mutations in the bcr-abl
tyrosine kinase domain in the majority of patients, and may be detected at low frequency
prior to TKI treatment in a subset of patients. Second generation TKIs, eg, dasatinib and
nilotinib,  show activity against most of  the bcr-abl tyrosine kinase domain (TKD) muta‐
tions involved in acquired imatinib resistance, but clinical benefit is generally short-lived.
Accordingly,  SCT in  first  complete  remission (CR)  is  considered to  be  the best  curative
option. Molecular monitoring of minimal residual disease levels appears to have prognos‐
tic  relevance  and should  be  used  to  guide  treatment.  International  standardization  and
quality control  efforts  are  ongoing to ensure comparability  of  results.  Mutation analysis
during treatment relies increasingly on highly sensitive PCR techniques or denaturing and
may assist in treatment decisions, e.g., in cases of molecular relapse. Results from current
studies of second-generation TKI as front-line treatment for Ph+ ALL are promising and
show high  molecular  response  rates,  but  follow-up is  still  too  short  to  determine  their
impact on remission duration and long-term survival. Strategies to improve outcome after
SCT include the pre-emptive use of imatinib, which appears to reduce the relapse rate. In
patients ineligible for transplantation,  novel  concepts for maintenance therapy are need‐
ed. These could involve novel immunotherapeutic interventions and combinations of TKI.
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